Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
Steininger
R
R
1. Chirurgische Universitätsklinik Wien, Vienna University Medical School, Austria.
Mühlbacher
F
F
Hamilton
G
G
Längle
F
F
Gnant
M
M
Popow
T
T
Sautner
T
T
Götzinger
P
P
Wamser
P
P
Stockenhuber
F
F
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000453:epidemiology / Q000209:etiology; D001706:Biopsy; D003524:Cyclosporins / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D015994:Incidence; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D008875:Middle Aged; D016853:Muromonab-CD3; D009181:Mycoses / Q000453:epidemiology / Q000209:etiology; D012189:Retrospective Studies; D014777:Virus Diseases / Q000453:epidemiology / Q000209:etiology
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D003524:Cyclosporins; D016853:Muromonab-CD3